FDA Approves New Indication for Envarsus XR (tacrolimus extended-release tablets)

COPENHAGEN, Denmark, Dec. 19, 2018 /PRNewswire/ — Veloxis Pharmaceuticals announced today that the U.S. Food & Drug Administration (FDA) approved a new indication for Envarsus XR (tacrolimus extended-release tablets) to prevent organ rejection in de novo kidney transplant patients in combination with other immunosuppressants. This indication is commonly referred to as the de novo indication. Envarsus XR was approved for […]

Read more

Editorial: Stop allowing beliefs to get in the way of treating opioid use disorder

There is a breadth of academic research demonstrating that there are three medications that successfully treat opioid use disorder (OUD): methadone, buprenorphine, and naltrexone. However, patients face unnecessary barriers to evidence-based treatment from government regulations as well as providers’ own beliefs that are not grounded in science, researchers from the Grayken Center for Addiction at Boston Medical Center (BMC) said […]

Read more
1 3 4 5